Welcome to our dedicated page for Y-Mabs Therapeutics SEC filings (Ticker: YMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Y-mAbs Therapeutics, Inc. (YMAB) SEC filings archive on this page provides a record of the company’s historical regulatory disclosures as a former Nasdaq-listed issuer and documents its transition to a privately held subsidiary of an affiliate of SERB Pharmaceuticals. While Y-mAbs has since terminated registration of its common stock and suspended its reporting obligations, these filings remain an important source of information for understanding its past operations, capital structure, and corporate transactions.
Among the most significant filings for Y-mAbs are its current reports on Form 8-K. A Form 8-K dated August 5, 2025 describes the Agreement and Plan of Merger between Y-mAbs, Perseus BidCo US, Inc. (Parent), and Yosemite Merger Sub, Inc. (Purchaser), under which Parent agreed to cause Purchaser to commence a cash tender offer for all outstanding shares of Y-mAbs common stock at $8.60 per share. A subsequent Form 8-K dated September 16, 2025 reports the completion of the tender offer and the merger under Section 251(h) of the Delaware General Corporation Law, the resulting change of control, and the conversion of each outstanding share (other than specified excluded shares) into the right to receive the cash merger consideration.
These 8-K filings also explain the delisting and deregistration process. In connection with the merger, Y-mAbs requested that the Nasdaq Global Select Market suspend trading in its common stock and file a Form 25 to remove the shares from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The Form 25-NSE filed on September 16, 2025 by Nasdaq Stock Market LLC serves as the official notification of removal from listing and/or registration. A later Form 15, filed on September 26, 2025, certifies the termination of registration under Section 12(g) and the suspension of Y-mAbs’ duty to file periodic reports under Sections 13 and 15(d). The Form 15 notes that the approximate number of holders of record at the certification date was one.
Earlier and contemporaneous filings, including Forms 10-K and 10-Q referenced in company press releases, contain detailed financial statements, risk factors, and management discussion and analysis related to Y-mAbs’ commercial-stage biopharmaceutical business. These documents discuss revenue from DANYELZA® (naxitamab-gqgk), research and development expenses for SADA PRIT programs such as GD2-SADA and CD38-SADA, selling, general, and administrative costs, and other operating metrics. While these periodic reports are no longer being updated following deregistration, they provide historical context on the company’s financial profile and R&D investment patterns during its time as a public company.
For those examining equity and compensation structures, the merger-related 8-K details the treatment of stock options, restricted stock units (RSUs), and performance-based RSUs (PSUs) at the effective time of the merger, including cash-out provisions and cancellation of options with exercise prices at or above the merger consideration. Additional filings, such as proxy statements and Section 16 reports (Forms 3, 4, and 5), historically provided insight into director and executive equity holdings and changes in beneficial ownership.
On this page, Stock Titan surfaces Y-mAbs’ historical SEC filings with real-time retrieval from EDGAR and AI-powered summaries that explain the core points of each document in accessible language. Users can quickly identify key merger terms, delisting steps, and financial reporting highlights without reading every page of the underlying forms. For deeper analysis, the full-text filings remain available for review, allowing investors, researchers, and legal or compliance professionals to trace the complete regulatory history of Y-mAbs Therapeutics, Inc. under the former ticker YMAB.
Transaction overview: Y-mAbs Therapeutics, Inc. entered into a Merger Agreement dated August 4, 2025 with Perseus BidCo US, Inc. (Parent), Yosemite Merger Sub, Inc. (Purchaser) and Stark International Lux. Purchaser will commence a cash Tender Offer of $8.60 per Share for all outstanding common stock, without interest and subject to applicable withholding taxes. If successful, the Tender Offer will be followed by a merger under Section 251(h) of the Delaware General Corporation Law, with the Company surviving the Merger.
Communications included: This Schedule 14D-9 consists of communications dated August 5, 2025, incorporated as Exhibits 99.1–99.6: a joint press release, an employee email, an investor/analyst letter, a patient and advocacy organization letter, a vendor/supplier letter, and a LinkedIn post.